A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
AbstractBackground. Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbation
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 June 2019
|
| In: |
Annals of oncology
Year: 2019, Jahrgang: 30, Heft: 9, Pages: 1487-1495 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdz199 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1093/annonc/mdz199 Verlag, Volltext: https://academic.oup.com/annonc/article/30/9/1487/5523176 
|
| Verfasserangaben: | O. Türeci, U. Sahin, H. Schulze-Bergkamen, Z. Zvirbule, F. Lordick, D. Koeberle, P. Thuss-Patience, T. Ettrich, D. Arnold, F. Bassermann, S.E. Al-Batran, K. Wiechen, K. Dhaene, D. Maurus, M. Gold, C. Huber, A. Krivoshik, A. Arozullah, J.W. Park, M. Schuler |
| Zusammenfassung: | AbstractBackground. Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbation |
|---|---|
| Beschreibung: | Gesehen am 09.01.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdz199 |